doi: 10.1002/1097-0142(197602)37:2<684::aid-cncr2820370212>3.0.co;2-y.
Intralesional BCG in the treatment of metastatic malignant melanoma
- PMID: 766947
- DOI: 10.1002/1097-0142(197602)37:2<684::aid-cncr2820370212>3.0.co;2-y
Item in Clipboard
Intralesional BCG in the treatment of metastatic malignant melanoma
Cancer.
1976 Feb.
Abstract
The therapeutic efficacy of intralesional BCG (Bacillus Calmette-Guerin; one immunizing dose every 2 weeks for a minimum of five treatments) was studied in 19 melanoma patients. Of 15 patients evaluable for response, five experienced significant objective improvement (two complete and three partial remissions). Objective improvement was limited to those patients with dermal metastatic disease. In vitro cytotoxicity in the presence of patient's serum bore, on average, a relationship to the clinical disease. In certain individual cases, serum blocking and/or lymphocyte stimulation may have had prognostic significance.
Similar articles
-
Immunotherapy of melanoma with intralesional BCG.Natl Cancer Inst Monogr. 1973 Dec;39:213-20. Natl Cancer Inst Monogr. 1973. PMID: 4595320 No abstract available.
-
Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.Cancer. 1978 Jun;41(6):2456-63. doi: 10.1002/1097-0142(197806)41:6<2456::aid-cncr2820410654>3.0.co;2-b. Cancer. 1978. PMID: 657108 Clinical Trial.
-
The use of oral BCG in the treatment or metastatic malignant melanoma.Med Pediatr Oncol. 1976;2(2):173-81. doi: 10.1002/mpo.2950020207. Med Pediatr Oncol. 1976. PMID: 785199
-
Immunology and cutaneous malignant melanoma.Int J Dermatol. 1976 Jan-Feb;15(1):1-18. doi: 10.1111/j.1365-4362.1976.tb05089.x. Int J Dermatol. 1976. PMID: 1107238 Review. No abstract available.
-
Clinical and molecular insights into BCG immunotherapy for melanoma.J Intern Med. 2020 Dec;288(6):625-640. doi: 10.1111/joim.13037. Epub 2020 Mar 4. J Intern Med. 2020. PMID: 32128919 Review.
Cited by
-
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Oncoimmunology. 2012 Sep 1;1(6):894-907. doi: 10.4161/onci.20931. Oncoimmunology. 2012. PMID: 23162757 Free PMC article.
-
Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.Crit Rev Oncog. 2016;21(1-2):65-73. doi: 10.1615/CritRevOncog.2016017124. Crit Rev Oncog. 2016. PMID: 27481003 Free PMC article. Review.
-
Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.PLoS One. 2013 Jul 17;8(7):e68561. doi: 10.1371/journal.pone.0068561. Print 2013. PLoS One. 2013. PMID: 23874673 Free PMC article.
-
Immune response and non-specific immunotherapy in melanoma.Ann R Coll Surg Engl. 1978 Mar;60(2):117-20. Ann R Coll Surg Engl. 1978. PMID: 637492 Free PMC article.
-
Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.Clin Exp Immunol. 1979 Oct;38(1):92-8. Clin Exp Immunol. 1979. PMID: 393441 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources